Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
Pyxis Oncology, a clinical stage company developing next-gen cancer therapies, announced its participation in the BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Lara S. Sullivan, M.D., President and CEO of Pyxis, along with other management members, will engage in one-on-one meetings during the conference.
This participation highlights Pyxis Oncology's commitment to advancing its pipeline of therapeutics targeting difficult-to-treat cancers. The company's presence at this virtual event provides an opportunity for investors and industry professionals to gain insights into Pyxis's ongoing developments and strategic direction in the oncology field.
Pyxis Oncology, un'azienda in fase clinica che sviluppa terapie oncologiche di nuova generazione, ha annunciato la sua partecipazione alla BTIG Virtual Biotechnology Conference. L'evento è programmato per il 5-6 agosto 2024. Lara S. Sullivan, M.D., Presidente e CEO di Pyxis, insieme ad altri membri della direzione, parteciperà a incontri individuali durante la conferenza.
Questa partecipazione sottolinea l'impegno di Pyxis Oncology nell'avanzare il suo portafoglio di terapie mirate a tumori difficili da trattare. La presenza dell'azienda a questo evento virtuale offre un'opportunità agli investitori e ai professionisti del settore di acquisire informazioni sui progressi in corso di Pyxis e sulla sua direzione strategica nel campo dell'oncologia.
Pyxis Oncology, una empresa en etapa clínica que desarrolla terapias oncológicas de nueva generación, anunció su participación en la BTIG Virtual Biotechnology Conference. El evento está programado para el 5-6 de agosto de 2024. Lara S. Sullivan, M.D., Presidenta y CEO de Pyxis, junto con otros miembros de la dirección, participarán en reuniones uno a uno durante la conferencia.
Esta participación destaca el compromiso de Pyxis Oncology con el avance de su cartera de terapias dirigidas a cánceres difíciles de tratar. La presencia de la empresa en este evento virtual proporciona una oportunidad para que inversores y profesionales de la industria obtengan información sobre los desarrollos en curso de Pyxis y su dirección estratégica en el campo de la oncología.
파이시스 온콜로지(Pyxis Oncology), 차세대 암 치료제를 개발하는 임상 단계 기업이 BTIG 가상 생명공학 컨퍼런스(BTIG Virtual Biotechnology Conference)에 참여한다고 발표했습니다. 이 행사는 2024년 8월 5-6일로 예정되어 있습니다. Lara S. Sullivan, M.D., 파이시스의 회장 겸 CEO는 다른 경영진들과 함께 컨퍼런스 동안 일대일 미팅에 참여할 예정입니다.
이번 참여는 파이시스 온콜로지의 치료제 파이프라인을 발전시키겠다는 의지를 강조합니다. 이 가상 행사에 참석함으로써 투자자들과 업계 전문가들이 파이시스의 진행 중인 개발 및 종양학 분야에서의 전략적 방향에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Pyxis Oncology, une entreprise en phase clinique développant des thérapies innovantes contre le cancer, a annoncé sa participation à la BTIG Virtual Biotechnology Conference. L'événement est prévu pour les 5 et 6 août 2024. Lara S. Sullivan, M.D., présidente et directrice générale de Pyxis, ainsi que d'autres membres de la direction, participeront à des réunions individuelles pendant la conférence.
Cette participation met en évidence l'engagement de Pyxis Oncology à faire progresser son portefeuille de thérapeutiques ciblant des cancers difficiles à traiter. La présence de l'entreprise à cet événement virtuel offre aux investisseurs et aux professionnels de l'industrie l'occasion d'obtenir des informations sur les développements en cours et l'orientation stratégique de Pyxis dans le domaine de l'oncologie.
Pyxis Oncology, ein Unternehmen in der klinischen Phase, das an der Entwicklung von next-gen Krebstherapien arbeitet, gab seine Teilnahme an der BTIG Virtual Biotechnology Conference bekannt. Die Veranstaltung ist für den 5.-6. August 2024 geplant. Lara S. Sullivan, M.D., Präsidentin und CEO von Pyxis, wird zusammen mit anderen Mitgliedern des Managements während der Konferenz an Einzelgesprächen teilnehmen.
Diese Teilnahme unterstreicht das Engagement von Pyxis Oncology, ihr Portfolio an Therapeutika für schwer zu behandelnde Krebserkrankungen voranzutreiben. Die Präsenz des Unternehmens bei dieser virtuellen Veranstaltung bietet Investoren und Fachleuten aus der Branche die Möglichkeit, Einblicke in die laufenden Entwicklungen und die strategische Ausrichtung von Pyxis im Bereich der Onkologie zu gewinnen.
- None.
- None.
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held August 5-6, 2024.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for mono and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Annual Report on Form 10-K filed with SEC on March 21, 2024, and our other filings, each of which is on file with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Pyxis Oncology Contact
Pamela Connealy
CFO and COO
ir@pyxisoncology.com
FAQ
When is Pyxis Oncology (PYXS) participating in the BTIG Virtual Biotechnology Conference?
Who from Pyxis Oncology (PYXS) will be attending the BTIG Virtual Biotechnology Conference?
What type of meetings will Pyxis Oncology (PYXS) be conducting at the BTIG Virtual Biotechnology Conference?
What is the focus of Pyxis Oncology's (PYXS) research and development?
